Clinical Trials in New Mexico
New Mexico has 31 clinical trials currently recruiting participants, ranking #41 among all states. The most-studied condition is Autism Spectrum Disorder with 2 active trials.
31
Total Trials
31
Recruiting
#41
National Rank
13
Conditions
Trials by Phase
1
Phase 1 / Phase 2
2
Phase 2 / Phase 3
14
Not Applicable
2
Phase 1
4
Phase 2
7
Phase 3
1
Phase 4
Top Conditions in New Mexico
Top Sponsors in New Mexico
Cities With Most Trials in New Mexico
| # | City | Trials |
|---|---|---|
| 1 | Albuquerque | 27 |
| 2 | Shiprock | 2 |
| 3 | Alamogordo | 1 |
| 4 | Santa Fe | 1 |
| 5 | Las Cruces | 1 |
| 6 | Gallup | 1 |
Important: This information is for research purposes only. Always talk to your doctor about whether a clinical trial is right for you.
Frequently Asked Questions
New Mexico currently has 31 clinical trials actively recruiting participants, making it #41 nationally by total trial count.
The most-studied conditions in New Mexico are Autism Spectrum Disorder (2 trials), Substance Use (2 trials), Non-small Cell Lung Cancer (2 trials).
Browse the conditions listed on this page to find trials recruiting in New Mexico. Each condition page shows trial details, eligibility criteria in plain English, and contact information. Always talk to your doctor about whether a trial is right for you.
Trial counts reflect currently recruiting studies listed on ClinicalTrials.gov with locations in this state.
The this entity category groups every U.S. clinical trials and research registries entity sharing this attribute. The list above is the data; the paragraphs below explain what the grouping means against the broader the NIH ClinicalTrials.gov registry distribution and how to read the relative rankings within the category.
For readers using this category as a starting point, the per-entity detail pages linked from the table above carry the underlying the NIH ClinicalTrials.gov registry data in full. The category-level view is the filter; the per-entity pages are the actual answer.
Source: ClinicalTrials.gov, 2026.